Novel, Highly Potent Aldose Reductase Inhibitors:  (R)-(−)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine- 4-spiro-3‘-pyrrolidine-1,2‘,3,5‘-tetrone (AS-3201) and Its Congeners

A series of novel tetrahydropyrrolo[1,2-a]pyrazine derivatives were synthesized and evaluated as aldose reductase inhibitors (ARIs) on the basis of their abilities to inhibit porcine lens aldose reductase (AR) in vitro and to inhibit sorbitol accumulation in the sciatic nerve of streptozotocin-induced diabetic rats in vivo. Of these compounds, spirosuccinimide-fused tetrahydropyrrolo[1,2-a]pyrazine-1,3-dione derivatives showed significantly potent AR inhibitory activity. In the in vivo activity of these derivatives, 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3‘-pyrrolidine-1,2‘,3,5‘-tetrone (<BO>23t</BO>) (SX-3030) showed the best oral activity. The enantiomers of <BO>23t</BO> were synthesized, and the biological activities were evaluated. It was found that AR inhibitory activity resides in the (−)-enantiomer <BO>43 </BO>(AS-3201), which was 10 times more potent in inhibition of the AR (IC<INF>50</INF> = 1.5 × 10^-8 M) and 500 times more potent in the in vivo activity (ED<INF>50</INF> = 0.18 mg/kg/day for 5 days) than the corresponding (+)-enantiomer <BO>44</BO> (SX-3202). From these results, AS-3201 was selected as the candidate for clinical development. The absolute configuration of AS-3201 was also established to be (R)-form by single-crystal X-ray analysis. In this article we report the preparation and structure−activity relationship (SAR) of tetrahydropyrrolopyrazine derivatives including a novel ARI, AS-3201.